Improving CAR T cell therapy for brain tumors using immune competent models
使用免疫活性模型改善脑肿瘤的 CAR T 细胞疗法
基本信息
- 批准号:10732795
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:Adoptive TransferAdultAdverse effectsAmericanAntigen TargetingAntigensBiologicalBrain NeoplasmsCAR T cell therapyCBLB geneCD276 geneCD28 geneCRISPR screenCRISPR/Cas technologyCell CycleCell surfaceCellsCellular immunotherapyChemotherapy and/or radiationChildhoodChildhood Brain NeoplasmClinicalClinical ResearchCore FacilityDiseaseDown-RegulationEngineeringGenerationsGenesGeneticGliomaGoalsHematologic NeoplasmsHeterogeneityHomingIL3RA geneImageImmuneImmune responseImmunocompetentImmunologyImmunotherapyImpaired cognitionImpairmentIn VitroInflammatoryInterventionLifeMacrophageMediatingMediatorMemoryModelingModificationMolecularMusMutateOperative Surgical ProceduresOutcomePatientsPenetrationPerformancePersonsPhasePhenotypePlayPositioning AttributePre-Clinical ModelPrimary Brain NeoplasmsProliferatingReceptor SignalingResearchResearch PersonnelResistanceRoleSafetySaint Jude Children&aposs Research HospitalShapesSubgroupT-Cell ActivationT-Cell Homing ReceptorsT-Cell ReceptorT-LymphocyteTCR ActivationTechniquesTestingTrainingTransmembrane DomainTumor AntigensTumor-associated macrophagesXenograft Modelantigen-specific T cellsantitumor effectcareerchimeric antigen receptorchimeric antigen receptor T cellscytokinecytotoxicitydesignengineered T cellsexhaustionextracellulargenome wide screenhuman diseaseimmune cell infiltrateimprovedimproved outcomein vitro activityin vivoinnovative technologiesinterestmotor impairmentmouse modelneoplastic cellnovelprototypereceptorresearch clinical testingsuccesstargeted treatmenttooltraffickingtranscriptomicstumortumor microenvironmenttumor xenografttumor-immune system interactions
项目摘要
PROJECT SUMMARY/ABSTRACT
The overall objective of this study is to engineer a potent CAR T cell therapy for high grade glioma (HGG),
a subgroup of brain tumors for which outcomes remain poor. CAR T cell therapy is an innovative technology
based on adoptive transfer of antigen-specific T cells engineered to elicit a clinically effective and specific
immune response against tumor cells. Early clinical studies in HGG patients demonstrated safety of CAR T cell
therapy for brain tumors; yet, only limited benefits were observed. Lack of efficacy is most likely multifactorial
and include heterogenous antigen expression, limited homing to and penetration of tumors, T cell exhaustion
and limited persistence, as well as the immunosuppressive tumor microenvironment (TME). Therefore, the
central hypothesis of this proposal is that optimized design and additional genetic modifications of CAR
T cells will improve their antitumor effects, and that these interventions will be evaluated in immune
competent mouse models that closely mimic human disease. Three interrelated research aims are proposed
to test this hypothesis and the rationale of each is outlined below. First, CAR design has to be optimized and
evaluated in immune competent glioma models. In Aim 1, I will generate CAR T cells containing different co-
stimulatory domains (CD28.ζ, 41BB.ζ, CD28.mutζ, and 41BB.mutζ), and compare their activity in vitro and in
vivo. Second, a genome wide screen in primary T cells has identified key regulators of T cell activation post T-
cell receptor (TCR) stimulation. Identified genes belong to molecules that regulate cell cycle, proliferation, and
downstream TCR signaling including SOCS1, RASA2, or CBLB. In Aim 2, I will therefore explore if CRISPR-
Cas9 mediated silencing of Socs1, Rasa2, and/or Cblb enhances the effector functions of CAR T cells. The
independent Aim 3 will then explore a dual CAR targeting approach in which I will not only target glioma cells
but also immunosuppressive cells within the glioma microenvironment. These studies are focused on tumor
associated macrophages (TAMs), since they are abundantly present in gliomas and play a critical role in shaping
the TME. To support the feasibility of this project, I have adapted the well-established immune competent GL261
glioma model to study CAR T cell therapies targeting the relevant tumor antigen B7-H3, which is not only
expressed by GL261 cells but also in a broad range of pediatric and adult brain tumors. In addition, my
preliminary studies indicate that `prototype' B7- H3 CAR T-cells readily recognize and kill GL261 cells in vitro
and have antitumor activity in vivo, highlighting that the developed model is well suited for the proposed aims of
this project. State of the art technique will be used in all three Aims to not only study the function and in vivo fate
of CAR T-cells, but also their antitumor activity, and how CAR T-cells interact with glioma- infiltrating immune
cells. Completion of this study will define the most optimal CAR design that best controls HGG tumors and
persists longer in the context of inflammatory brain tumors. Additionally, results will illustrate if targeting TAMs
will overcome the suppressive effects of TME on B7-H3 CAR T cells.
项目总结/摘要
本研究的总体目标是设计一种有效的CAR T细胞疗法用于高级别胶质瘤(HGG),
这是一个预后不佳的脑肿瘤亚组。CAR T细胞疗法是一项创新技术
基于抗原特异性T细胞的过继转移,所述抗原特异性T细胞被工程化以引起临床有效和特异性的免疫应答。
对肿瘤细胞的免疫反应。HGG患者的早期临床研究证明了CAR T细胞的安全性
脑肿瘤的治疗;然而,仅观察到有限的益处。缺乏疗效很可能是多因素造成的
包括异质性抗原表达、有限的肿瘤归巢和穿透、T细胞耗竭
和有限的持久性,以及免疫抑制肿瘤微环境(TME)。因此
该建议的中心假设是CAR的优化设计和额外的遗传修饰
T细胞将提高其抗肿瘤作用,这些干预措施将在免疫系统中进行评估。
非常接近人类疾病的小鼠模型。提出了三个相互关联的研究目标
以检验这一假设,每个假设的基本原理概述如下。首先,CAR设计必须优化,
在免疫活性胶质瘤模型中进行评估。在目标1中,我将产生含有不同共-
刺激结构域(CD 28.ζ、41 BB.ζ、CD28.mutζ和41BB.mutζ),并比较它们在体外和体内的活性
vivo.第二,在原代T细胞中的全基因组筛选已经鉴定了T细胞活化后T细胞活化的关键调节因子。
细胞受体(TCR)刺激。已鉴定的基因属于调节细胞周期、增殖和增殖的分子,
下游TCR信号传导包括SOCS 1、RASA 2或CBLB。因此,在目标2中,我将探讨CRISPR-
Cas9介导的Socs 1、Rasa 2和/或Cblb沉默增强CAR T细胞的效应子功能。的
然后,独立的Aim 3将探索双重CAR靶向方法,其中我不仅靶向胶质瘤细胞,
还包括神经胶质瘤微环境中的免疫抑制细胞。这些研究集中在肿瘤
相关巨噬细胞(TAM),因为它们大量存在于胶质瘤中,并在形成胶质瘤中发挥关键作用。
的TME。为了支持这个项目的可行性,我已经适应了完善的免疫能力GL 261
神经胶质瘤模型研究靶向相关肿瘤抗原B7-H3的CAR T细胞疗法,这不仅是
它不仅在GL 261细胞中表达,而且在广泛的儿童和成人脑肿瘤中表达。另外我
初步研究表明,“原型”B7- H3 CAR T细胞在体外容易识别并杀死GL 261细胞
并具有体内抗肿瘤活性,突出表明所开发的模型非常适合于所提出的目标,
这个项目在所有三个目的中将使用最先进的技术,不仅研究功能和体内命运,
CAR T细胞,以及它们的抗肿瘤活性,以及CAR T细胞如何与神经胶质瘤浸润性免疫细胞相互作用。
细胞这项研究的完成将确定最佳控制HGG肿瘤的最佳CAR设计,
在炎性脑肿瘤中持续时间更长。此外,结果将说明,如果靶向TAM
将克服TME对B7-H3 CAR T细胞的抑制作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dalia Haydar其他文献
Dalia Haydar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dalia Haydar', 18)}}的其他基金
Improving CAR T cell therapy for brain tumors using immune competent models
使用免疫活性模型改善脑肿瘤的 CAR T 细胞疗法
- 批准号:
10322192 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




